Lowest-Rated StocksLowest-RatedNASDAQ:SAGE Sage Therapeutics (SAGE) Stock Price, News & Analysis $6.52 +0.04 (+0.62%) Closing price 04:00 PM EasternExtended Trading$6.52 +0.01 (+0.08%) As of 04:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Sage Therapeutics Stock (NASDAQ:SAGE) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Sage Therapeutics alerts:Sign Up Key Stats Today's Range$6.46▼$6.6050-Day Range$6.38▼$8.6652-Week Range$4.62▼$13.47Volume736,464 shsAverage Volume1.19 million shsMarket Capitalization$408.29 millionP/E RatioN/ADividend YieldN/APrice Target$8.87Consensus RatingHold Company OverviewSage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression. Its product pipeline also comprises SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases; and SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which is in Phase II clinical trial for the treatment of depression, Huntington's disease, Parkinson's diseases, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. The company has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.Read More… Sage Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks76th Percentile Overall ScoreSAGE MarketRank™: Sage Therapeutics scored higher than 76% of companies evaluated by MarketBeat, and ranked 258th out of 933 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.0 / 5Analyst RatingHold Consensus RatingSage Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.06, and is based on 2 buy ratings, 14 hold ratings, and 1 sell rating.Amount of Analyst CoverageSage Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Sage Therapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Sage Therapeutics are expected to grow in the coming year, from ($3.52) to ($2.52) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Sage Therapeutics is -0.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Sage Therapeutics is -0.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSage Therapeutics has a P/B Ratio of 0.86. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Sage Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted9.09% of the float of Sage Therapeutics has been sold short.Short Interest Ratio / Days to CoverSage Therapeutics has a short interest ratio ("days to cover") of 4.4.Change versus previous monthShort interest in Sage Therapeutics has recently increased by 7.28%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSage Therapeutics does not currently pay a dividend.Dividend GrowthSage Therapeutics does not have a long track record of dividend growth. Sustainability and ESG4.0 / 5Environmental Score-1.83 Percentage of Shares Shorted9.09% of the float of Sage Therapeutics has been sold short.Short Interest Ratio / Days to CoverSage Therapeutics has a short interest ratio ("days to cover") of 4.4.Change versus previous monthShort interest in Sage Therapeutics has recently increased by 7.28%, indicating that investor sentiment is decreasing significantly. News and Social Media2.9 / 5News Sentiment1.17 News SentimentSage Therapeutics has a news sentiment score of 1.17. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.87 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Sage Therapeutics this week, compared to 8 articles on an average week.Search Interest2 people have searched for SAGE on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Sage Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.50% of the stock of Sage Therapeutics is held by insiders.Percentage Held by Institutions99.22% of the stock of Sage Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Sage Therapeutics' insider trading history. Receive SAGE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sage Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address SAGE Stock News HeadlinesBrokerages Set Sage Therapeutics, Inc. (NASDAQ:SAGE) PT at $8.81May 20, 2025 | americanbankingnews.comSage Therapeutics (NASDAQ:SAGE) Lowered to Sell Rating by StockNews.comMay 20, 2025 | americanbankingnews.comHow Trade Wars Are Creating Fresh Opportunities for InvestorsTariffs and trade tensions are back in the headlines, and while many are focused on the risks, smart investors know there’s also opportunity. New supply chain shifts, pricing power adjustments, and sector revaluations are already underway—creating openings for those who act early. That’s why we’ve just released our latest research: 📈 “From Tariffs to Returns: How to Capitalize on Trade Disputes in Your Portfolio”May 29, 2025 | Darwin (Ad)Neuromodulation: rewiring healthcare?May 19, 2025 | msn.comJ.P. Morgan Keeps Their Hold Rating on SAGE Therapeutics (SAGE)May 10, 2025 | theglobeandmail.comMajor Depressive Disorder Pipeline Report 2025: Comprehensive Insights of 75+ Companies and Drugs Under Clinical AssessmentMay 8, 2025 | finance.yahoo.comTrinity Life Sciences Announces Winners of TGaS Advisors Best of Benchmark Awards for Operational Excellence in Pharma IndustryMay 6, 2025 | finance.yahoo.comQ1 2025 SAGE Therapeutics Inc Earnings CallMay 1, 2025 | finance.yahoo.comSee More Headlines SAGE Stock Analysis - Frequently Asked Questions How have SAGE shares performed this year? Sage Therapeutics' stock was trading at $5.43 at the beginning of 2025. Since then, SAGE stock has increased by 20.0% and is now trading at $6.5150. View the best growth stocks for 2025 here. How were Sage Therapeutics' earnings last quarter? Sage Therapeutics, Inc. (NASDAQ:SAGE) released its quarterly earnings results on Tuesday, April, 29th. The biopharmaceutical company reported ($1.01) EPS for the quarter, missing the consensus estimate of ($0.99) by $0.02. The company's revenue for the quarter was up 78.0% compared to the same quarter last year. Read the conference call transcript. Who are Sage Therapeutics' major shareholders? Sage Therapeutics' top institutional investors include Vanguard Group Inc. (8.11%), TIG Advisors LLC (4.36%), Boothbay Fund Management LLC (2.21%) and Federated Hermes Inc. (1.90%). View institutional ownership trends. How do I buy shares of Sage Therapeutics? Shares of SAGE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Sage Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Sage Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Netflix (NFLX), JPMorgan Chase & Co. (JPM) and Visa (V). Company Calendar Last Earnings4/29/2025Today5/29/2025Next Earnings (Estimated)7/30/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:SAGE CIK1597553 Webwww.sagerx.com Phone(617) 299-8380Fax617-299-8379Employees690Year FoundedN/APrice Target and Rating Average Stock Price Target$8.87 High Stock Price Target$16.00 Low Stock Price Target$4.00 Potential Upside/Downside+35.4%Consensus RatingHold Rating Score (0-4)2.06 Research Coverage17 Analysts Profitability EPS (Most Recent Fiscal Year)($5.80) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$400.67 million Net Margins-971.50% Pretax Margin-971.48% Return on Equity-68.18% Return on Assets-60.84% Debt Debt-to-Equity RatioN/A Current Ratio7.42 Quick Ratio7.42 Sales & Book Value Annual Sales$47.40 million Price / Sales8.65 Cash FlowN/A Price / Cash FlowN/A Book Value$7.56 per share Price / Book0.87Miscellaneous Outstanding Shares62,621,000Free Float58,100,000Market Cap$410.17 million OptionableOptionable Beta0.20 Social Links Beginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (NASDAQ:SAGE) was last updated on 5/29/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredAs Bitcoin supply vanishes, this Trump-aligned token could explodeBitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sage Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sage Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.